(R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol → 9-[(R)-3-Hydroxy-3-(5-methyl-isoxazol-3-yl)-but-1-ynyl]-8-methyl-4,5-dihydro-6-oxa-1,3a-diaza-benzo[e]azulene-2-carboxylic acid amide
Reaktionsgleichung
Br[C:2]1[C:3]([CH3:19])=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[CH:12]=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]3[C:6]=2[CH:18]=1.[CH3:20][C:21]1[O:25][N:24]=[C:23]([C@:26]([OH:30])([C:28]#[CH:29])[CH3:27])[CH:22]=1>>[OH:30][C@:26]([C:23]1[CH:22]=[C:21]([CH3:20])[O:25][N:24]=1)([CH3:27])[C:28]#[C:29][C:2]1[C:3]([CH3:19])=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[C:7](=[N:14][C:13]([C:15]([NH2:17])=[O:16])=[CH:12]3)[C:6]=2[CH:18]=1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
Following Procedure F, 10-bromo-9-methyl-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with (2R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol to give the titled compound as a colorless solid after purification by reverse-phase HPLC. LCMS: 393.1 [M+H]+; 1H NMR (400 MHz, DMSO) δ 8.46 (s, 1H), 7.76 (s, 1H), 7.49 (s, 1H), 7.08 (s, 1H), 7.03 (s, 1H), 6.95 (s, 1H), 6.45 (s, 1H), 6.35 (s, 1H), 4.46 (s, 4H), 2.41 (s, 3H), 2.34 (s, 3H), 1.81 (s, 3H).